ARTICLE | Market Access
U.K. paying for two antibiotics in world first subscription model
NICE’s QALY-based calculation for Zavicefta, Fetcroja goes far beyond simply modeling their health benefits
June 17, 2022 7:45 PM UTC
Two months after NICE published draft guidance estimating the value of Zavicefta and Fetcroja to the NHS, the health system came to an agreement with the drugs’ manufacturers on a subscription-based payment pilot that could serve as an example for other HTAs and payers considering antibiotic subscriptions.
The two drugs, Zavicefta ceftazidime/avibactam from Pfizer Inc. (NYSE:PFE) and Fetcroja cefiderocol (Fetroja in the U.S.) from Shionogi & Co. Ltd. (Tokyo:4507), were selected by NICE in December 2020 as the first in the pilot scheme, to treat serious infections including bloodstream infections, sepsis and hospital or ventilator acquired pneumonia (HAP and VAP)...